U.S. Markets closed

EDAP TMS S.A. (EDAP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.14+0.01 (+0.11%)
At close: 4:00PM EDT

EDAP TMS S.A.

Parc dActivites la Poudrette-Lamartine
4/6, rue du DauphinE Vaulx-en-Velin
Lyon 69120
France
33 4 72 15 31 50
http://www.edap-tms.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees223

Key Executives

NameTitlePayExercisedYear Born
Mr. Marc OczachowskiExec. Chairman & CEON/AN/A1970
Mr. François DietschChief Financial OfficerN/AN/A1976
Ms. Blandine ConfortInvestor Relations Officer and Sec.N/AN/AN/A
Mr. Frank Van HyfteVP of Global Sales & MarketingN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. It operates in two divisions, High Intensity Focused Ultrasound (HIFU) and Urological Devices and Services (UDS). The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer. It also provides disposables, and leasing and treatment related services; and maintenance services. The UDS division develops, markets, manufactures, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders primarily urinary stones and other clinical indications. This segment offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals; and Endo-UP platform, manages urinary stones, as well as Sonolith i-sys. It also leases lithotripters; sells disposables and spare parts; maintenance services; and distributes urodynamic products and urology lasers. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is headquartered in Lyon, France.

Corporate Governance

EDAP TMS S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.